Predicting EGFR T790M Mutation in Brain Metastases Using Multisequence MRI-Based Radiomics Signature

被引:9
|
作者
Li, Ye [1 ]
Lv, Xinna [1 ]
Wang, Bing [2 ]
Xu, Zexuan [1 ]
Wang, Yichuan [2 ]
Sun, Mengyan [1 ]
Hou, Dailun [1 ]
机构
[1] Capital Med Univ, Beijing Chest Hosp, Dept Radiol, Beijing, Peoples R China
[2] Beijing TB & Thorac Tumor Res Inst, Dept Radiol, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Radiomics; Magnetic Resonance Imaging; EGFR; T790M; Brain Metastases;
D O I
10.1016/j.acra.2022.12.030
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Rationale and Objectives: Timely identifying T790M mutation for non-small cell lung cancer (NSCLC) patients with brain metastases (BM) is essential to adjust targeted treatment strategies. To develop and validate radiomics models based on multisequence MRI for differenti-ating patients with T790M resistance from no T790M mutation in BM and explore the optimal sequence for prediction. Materials and Methods: This retrospective study enrolled 233 patients with proven of BM in NSCLC which included 95 with T790M and 138 without T790M from two hospitals as the training cohort and testing cohort separately. Radiomics features extracted from T2WI, T2 fluid-attenuated inversion recovery (T2-FLAIR), diffusion weighted imaging (DWI) and contrast-enhanced T1-weighted imaging (T1-CE) sequence respectively. The most predictable features were selected based on the maximal information coefficient and Boruta method. Then four radiomics models were built to characterize T790M mutation by random forest classifier. ROC curves, F1 score and DCA curves were constructed to validate the capability and verify the performance of four models.Results: The DWI model showed best performance with AUC and F1 score of 0.886 and 0.789 in the training cohort, 0.850 and 0.743 in the testing cohort. DCA curves also showed higher overall net benefit from the DWI model than from the remaining three models in the testing cohort. Other three models also had some classification power whether in the training or testing cohort, especially T2-FLAIR model.Conclusion: Multisequence MRI-based radiomics has potential to predict the emergence of EGFR T790M resistance mutations especially the radiomics signature based on DWI sequence.
引用
下载
收藏
页码:1887 / 1895
页数:9
相关论文
共 50 条
  • [31] Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study
    Zhengquan Yang
    Jialu Li
    Yujie Hu
    Meihua Chen
    Danli Peng
    Dan Zong
    Qingjuan Shang
    Lianqin Tao
    Yanling Zhao
    Yiyun Ni
    Jinyan Ye
    Yupeng Xie
    Li Yang
    Quan Lin
    Chang Cai
    Ning Xu
    Xiaoping Huang
    Xiaoting Dong
    Zhonghui Zhou
    Yali Yu
    Zongxiao Shangguan
    Yangyang Xu
    Weiping Ying
    Meiling Weng
    Zuguo Yuan
    Zhijun Dong
    Jifa Li
    Zhe Zheng
    Jiongwei Pan
    Lu Liu
    Junhui Ye
    Zhan Zhang
    Wenfeng Li
    Junfei Zhu
    Shengnan Jin
    Yuping Li
    Chunming Ding
    Targeted Oncology, 2019, 14 : 719 - 728
  • [32] EGFR T790M Mutation A Double Role in Lung Cancer Cell Survival?
    Suda, Kenichi
    Onozato, Ryoichi
    Yatabe, Yasushi
    Mitsudomi, Tetsuya
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (01) : 1 - 4
  • [33] Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation
    Maekinen, Netta
    Zhou, Meng
    Bemus, Meredith
    Nevin, Julius
    Nag, Anwesha
    Chen, Ruthia
    Colson, Yolonda L.
    Thorner, Aaron R.
    Oxnard, Geoffrey R.
    Meyerson, Matthew
    Sholl, Lynette M.
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (04):
  • [34] The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
    Kim, Youngwook
    Ko, Jeonghun
    Cui, ZhengYun
    Abolhoda, Amir
    Ahn, Jin Seok
    Ou, Sai-Hong
    Ahn, Myung-Ju
    Park, Keunchil
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (03) : 784 - 791
  • [35] Clinical Impact of Pretreatment EGFR T790M Mutation in Lung Adenocarcinoma Patients
    Macerola, Elisabetta
    Bruno, Rossella
    Prediletto, Irene
    Sensi, Elisa
    Chella, Antonio
    Landi, Lorenza
    Ali, Greta
    Fontanini, Gabriella
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1207 - S1207
  • [36] The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
    Kim, Youngwook
    Ko, Jeonghun
    Cui, Zhengyun
    Abolhoda, Amir
    Lee, Jeeyun
    Ahn, Jinseok
    Ou, Sai-Hong
    Ahn, Myung-Ju
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S421 - S421
  • [37] Germline EGFR T790M Mutation Found in Multiple Members of a Familial Cohort
    Yu, Helena A.
    Arcila, Maria E.
    Fleischut, Megan Harlan
    Stadler, Zsofia
    Ladanyi, Marc
    Berger, Michael F.
    Robson, Mark
    Riely, Gregory J.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : 554 - 558
  • [38] Monitoring the EGFR T790M mutation in liquid biopsy in patients with lung cancer
    Cardos, G.
    Motoc, R.
    Leonte, D. G. N.
    Simion, G.
    Gurban, P.
    Iordache, F.
    Iorga, P.
    Apostol, P. P.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 436 - 437
  • [39] Progressive Disease with T790M Mutation vs Non-T790M Mutation in EGFR Positive Patients Treated with Tyrosine Kinase Inhibitors
    Reis, D.
    China, N.
    Dias, M.
    Coutinho, D.
    Silva, E.
    Campainha, S.
    Costa, T.
    Conde, S.
    Cirnes, L.
    Barroso, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S942 - S943
  • [40] A Prospective Observational Study of Osimertinib Using Plasma Concentrations in NSCLC With Acquired EGFR T790M Mutation
    Nakagawa, T.
    Fukuhara, T.
    Imai, K.
    Igusa, R.
    Yokota, H.
    Watanabe, K.
    Suzuki, A.
    Morita, M.
    Inoue, A.
    Miura, M.
    Minamiya, Y.
    Maemondo, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S953 - S954